COVID-19 and Cancer Consortium Registry

Study Overview
=================
Brief Summary
-----------------
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.

Detailed Description
-----------------
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generating and hypothesis-supporting findings that are generalizable to the population at large. Specifically: I. Characterize patient factors, such as pre-existing comorbidities, baseline medication exposures, cancer type, status, and treatment, and demographic factors that are associated with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive), including severity and fatality, in patients with cancer. II. Describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation. III. Evaluate the association of COVID-19 with cancer outcomes.

Official Title
-----------------
The COVID-19 and Cancer Consortium (CCC19) Registry

Conditions
-----------------
COVID-19, Invasive Malignancy (Any Type)

Intervention / Treatment
-----------------
* Other: Web-based REDCap survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: • Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria: Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19. Current or past medical history of invasive malignancy (any type) Exclusion criteria: Participants at international sites not explicitly listed below Non-healthcare providers (or their proxies)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Web-based REDCap survey|The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Web-based REDCap survey | The survey includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes. | Approximately 18 months |